A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
Study of Drug in Patients with Epithelioid Hemangioendothelioma (EHE)
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAR4308
U.S. Govt. ID: NCT03148275
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the safety and effectiveness of the study drug in patients with Metastatic Epithelioid Hemangioendothelioma (EHE). The study drug is called trametinib. Trametinib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size. Trametinib has already been FDA-approved to treat other cancer. There will be up to 27 people taking part in this study.
This study is closed
Gary Schwartz, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with Epithelioid Hemangioendothelioma (EHE)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator